Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MHM-PI
- Development stage
- Unknown
- Lead developer
- Elan Vital
01
Overview
MHM-PI is an early-stage, conceptual pharmaceutical research candidate being investigated by Elan Vital. It is derived from the company's Green Red Bio Metabolome (GRBM) platform, which utilizes plant-microbe metabolome-derived materials. MHM-PI is classified at the QL5 level of the company's internal quality scheme, representing a long-term pharmaceutical candidate research item. Because it is in the conceptual research phase, no specific therapeutic targets, modalities, indications, or clinical development phases have been disclosed, and separate non-clinical and clinical studies along with regulatory approval would be required for further development.
Beyond the preview
Go deeper on MHM-PI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MHM-PI.